Clinical Trial Update: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

AstraZeneca is conducting a Phase 2 study of neoadjuvant and adjuvant therapy for resectable non-small cell lung cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING